Literature DB >> 29604480

Nonalcoholic fatty liver disease and advanced fibrosis are associated with left ventricular diastolic dysfunction.

Goh Eun Chung1, Jeong-Hoon Lee2, Heesun Lee1, Min Kyung Kim3, Jeong Yoon Yim1, Su-Yeon Choi1, Yoon Jun Kim2, Jung-Hwan Yoon2, Donghee Kim4.   

Abstract

BACKGROUND AND AIMS: Nonalcoholic fatty liver disease (NAFLD) may be associated with a wide spectrum of cardiac abnormalities, which share many metabolic risk factors. This study aimed to evaluate whether NAFLD is associated with left ventricular (LV) diastolic dysfunction independent of other classical risk factors.
METHODS: A total of 3300 subjects (mean age, 54.1 years; 62.9% men), who underwent echocardiography and hepatic ultrasonography, were enrolled. LV diastolic dysfunction was diagnosed and graded using conventional and Doppler echocardiographic assessments. NAFLD was diagnosed by ultrasonographic findings without any evidence of significant alcohol consumption or viral hepatitis, other liver diseases, or medication provoking fatty liver. Advanced fibrosis was defined as having intermediate-high probability for advanced fibrosis using the NAFLD fibrosis score.
RESULTS: The prevalence of LV diastolic dysfunction was 35.1%. NAFLD had a higher prevalence and severity of LV diastolic dysfunction. The prevalence rates of LV diastolic dysfunction were significantly increased according to the NAFLD fibrosis grade (30.4% for no-NAFLD, 35.2% for NAFLD without advanced fibrosis and 57.4% for NAFLD with advanced fibrosis, p < 0.001). Multivariable analysis showed that NAFLD was associated with a 29% increase in the risk of diastolic dysfunction compared with controls (odds ratio [OR] 1.29; 95% confidence interval [CI] 1.07-1.60). There was significant interaction between obesity (BMI < 25 kg/m2vs. ≥ 25 kg/m2) and advanced fibrosis for LV diastolic dysfunction. A significant, incrementally increased risk of diastolic dysfunction according to the fibrosis grade was more pronounced in the non-obese population [adjusted OR (95% CI), 1.40 (1.06-1.84) for NAFLD without advanced fibrosis, 1.44 (0.95-2.17) for NAFLD with advanced fibrosis vs. no NAFLD, P for trend = 0.022] compared with the obese population (p for trend = 0.081), independent of other well-defined risk factors.
CONCLUSIONS: NAFLD was associated with increased risk for LV diastolic dysfunction. In addition, an incrementally increased risk for LV diastolic dysfunction according to fibrosis grade was prominent in the non-obese population.
Copyright © 2018 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Fibrosis; Heart failure; Hepatic steatosis; Non-obese

Mesh:

Year:  2018        PMID: 29604480     DOI: 10.1016/j.atherosclerosis.2018.03.027

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  9 in total

Review 1.  Pathogenesis of non-alcoholic fatty liver disease and implications on cardiovascular outcomes in liver transplantation.

Authors:  Benedict J Maliakkal
Journal:  Transl Gastroenterol Hepatol       Date:  2020-07-05

2.  Association between cardiac conduction defect and nonalcoholic fatty liver disease: a systematic review and meta-analysis.

Authors:  Karn Wijarnpreecha; Panadeekarn Panjawatanan; Paul T Kroner; Wisit Cheungpasitporn; Patompong Ungprasert
Journal:  Ann Gastroenterol       Date:  2020-09-16

Review 3.  Epidemiology: Pathogenesis, and Diagnostic Strategy of Diabetic Liver Disease in Japan.

Authors:  Yoshio Sumida; Toshihide Shima; Yasuhide Mitsumoto; Takafumi Katayama; Atsushi Umemura; Kanji Yamaguchi; Yoshito Itoh; Masashi Yoneda; Takeshi Okanoue
Journal:  Int J Mol Sci       Date:  2020-06-18       Impact factor: 5.923

4.  Cirrhotic cardiomyopathy: An independent prognostic factor for cirrhotic patients.

Authors:  Yun Bin Lee; Jeong-Hoon Lee
Journal:  Clin Mol Hepatol       Date:  2018-12-11

5.  Western Diet-Fed, Aortic-Banded Ossabaw Swine: A Preclinical Model of Cardio-Metabolic Heart Failure.

Authors:  T Dylan Olver; Jenna C Edwards; Thomas J Jurrissen; Adam B Veteto; John L Jones; Chen Gao; Christoph Rau; Chad M Warren; Paula J Klutho; Linda Alex; Stephanie C Ferreira-Nichols; Jan R Ivey; Pamela K Thorne; Kerry S McDonald; Maike Krenz; Christopher P Baines; R John Solaro; Yibin Wang; David A Ford; Timothy L Domeier; Jaume Padilla; R Scott Rector; Craig A Emter
Journal:  JACC Basic Transl Sci       Date:  2019-06-24

6.  Significant Association Between Left Ventricular Diastolic Dysfunction, Left Atrial Performance and Liver Stiffness in Patients with Metabolic Syndrome and Non-Alcoholic Fatty Liver Disease.

Authors:  Tudor Parvanescu; Andrei Vitel; Ioan Sporea; Ruxandra Mare; Bogdan Buz; Diana Aurora Bordejevic; Mirela Cleopatra Tomescu; Sergiu Florin Arnautu; Vlad Ioan Morariu; Ioana Mihaela Citu
Journal:  Diabetes Metab Syndr Obes       Date:  2021-04-09       Impact factor: 3.168

7.  Association of Metabolic Dysfunction-Associated Fatty Liver Disease With Left Ventricular Diastolic Function and Cardiac Morphology.

Authors:  Dandan Peng; Zhenqiu Yu; Mingwei Wang; Junping Shi; Lei Sun; Yuanyuan Zhang; Wenbin Zhao; Chen Chen; Jiake Tang; Chunyi Wang; Jie Ni; Wen Wen; Jingjie Jiang
Journal:  Front Endocrinol (Lausanne)       Date:  2022-07-19       Impact factor: 6.055

8.  Non-obese NAFLD had no better cardio-metabolic risk profile than obese NAFLD in type 2 diabetic patients.

Authors:  Ziyin Zhang; Lu Zhang; Wangyan Jiang; Tingting Du; Gang Yuan
Journal:  Cardiovasc Diabetol       Date:  2022-10-14       Impact factor: 8.949

9.  The risk of atrial fibrillation in patients with non-alcoholic fatty liver disease and a high hepatic fibrosis index.

Authors:  Hyo Eun Park; Heesun Lee; Su-Yeon Choi; Hua Sun Kim; Goh Eun Chung
Journal:  Sci Rep       Date:  2020-03-19       Impact factor: 4.379

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.